Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Lung Cancer Lung Cancer for January/February 2020 Pembrolizumab plus chemoradiotherapy shows early promise in NSCLC, Medicaid expansion linked to more early cancer diagnoses, Tumor neoantigenicity metric improves prediction of response to immunotherapy, Global project reveals cancer’s genomic playbook, Walk test may predict complications after lung cancer surgery, More must reads Lung Cancer for November/December 2019 Standard-dose RT with concurrent chemo found superior for unresectable NSCLC, Benefits and Drawbacks Found for Risk-Based Lung Cancer Screening Tools, Patient-Reported Outcomes Support First-Line Pembrolizumab for NSCLC, Single-Fraction Radiation Misses Mark for Spinal Compression Relief, Neoantigen Vaccine Appears Safe and Active in NSCLC, More must readsLung Cancer for September/October 2019 Patients have good recall on lung cancer screening scan benefits, not risks, Stereotactic body radiation therapy safe, effective for moderately central NSCLC, Adding ramucirumab extends PFS in EGFR-mutated lung cancer, Lazertinib has good showing in EGFR-mutated advanced NSCLC, Ongoing and Intensified Molecular Testing Education Needed Globally, More must readsLung Cancer for July/August 2019 COPD Adds Complexity to Shared Decision Making for LDCT Lung Cancer Screening, Bevacizumab-Erlotinib Combo Fails to Improve Outcomes in EGFR-mutant Advanced NSCLC, Maintenance Therapy With Either Bevacizumab or Pemetrexed Efficacious for NSCLC, Immune-related Toxicities, Hospitalization Common with Checkpoint Inhibitor Therapy, Center’s Experience Casts Doubt on Clinical Utility of NGS, More must readsLung Cancer for May/June 2019 Repotrectinib Highly Active in ROS1-positive Lung Cancer, Checkpoint Inhibitor Rechallenge Possible for Select Patients, Pembrolizumab Improves 5-year OS in Advanced NSCLC, Low-dose CT Lung Cancer Screening Nets Payoff in Community Setting, Antibodies May Have Role in ‘TKI World’ of EGFR-mutant NSCLC, More must readsPages« first 1 2 3 4 5 6 7 last »
